Along with rising diagnoses for bipolar spectrum disorders, direct-to-consumer (DTC) advertisements for bipolar disorder treatments have increased in recent years. This study textually analyzes 25 ads from the brands Vraylar, Caplyta, and Latuda based on the theory and method of Hall, and supported by the work of Goffman and Thoits on stigma. Findings show that ads embodied the ambivalence associated with the spectacle of the other. Additionally, ads largely ignored the stigma of bipolar disorder, placing emphasis on the “in-between” phase where protagonists receive treatment. This emphasis on the “in-between” often creates a fetishized view of the protagonist with ill mental health.
AnS.KangH. (2011). Stigma-reducing components in direct-to-consumer prescription ads: Onset controllability, offset controllability, and recategorization. Health Communication, 26(5), 468–478. https://doi.org/10.1080/10410236.2011.554169
2.
AngstJ.GammaA.BenazziF.AjdacicV.EichD.RosslerW. (2003). Toward a re-definition of subthreshold bipolarity: Epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. Journal of Affective Disorders, 73(1-2), 133–146. https://doi.org/10.1016/S0165-0327(02)00322-1
3.
AppignanesiL. (2008). Mad, bad and sad: Women and the mind doctors. W.W. Norton & Company.
4.
ApplequistJ.BallJ. G. (2018). An updated analysis of direct-to-consumer television advertisements for prescription drugs. Annals of Family Medicine, 16(3), 211–216. https://doi.org/10.1370/afm.2220
5.
ArneyJ.MenjivarC. (2014). Disease Mongering in direct-to-consumer advertising and the expansion of the antidepressant market. Sociological Inquiry, 84(4), 519–544. https://doi.org/10.1111/soin.12062
6.
ArneyJ.WeitzR. (2012). Gendering affective disorders in direct-to-consumer advertisements. In Jacobs KronenfeldJ. (Ed.), Issues in health and health care related to race/ethnicity, immigration, SES and gender (research in the sociology of health care) (Vol. 30, pp. 61–180). Emerald Group Publishing Limited. https://doi.org/10.1108/S0275-4959(2012)0000030010
7.
BellR. A.TaylorL. D.KravitzR. L. (2010). Do antidepressant advertisements educate consumers and promote communication between patients with depression and their physicians?Patient Education and Counseling, 81(2), 245–250. https://doi.org/10.1016/j.pec.2010.01.014
8.
CalfeeJ. (2002). Public policy issues in direct-to-consumer advertising of prescription drugs. Journal of Public Policy and Marketing, 21(2), 174–193. https://doi.org/10.1509/jppm.21.2.174.17580
9.
CoffeyA.AtkinsonP. (1996). Making sense of qualitative data: complementary research strategies. Sage.
10.
ConradP.LeiterV. (2008). From Lydia Pinkham to Queen Levitra: Direct-to-consumer advertising and medicalisation. Sociology of Health and Illness, 30(6), 825–838. https://doi.org/10.1111/j.1467-9566.2008.01092.x
11.
CorriganP. W.KosylukK. A.Konadu FokuoJ.ParkJ. H. (2014). How does direct to consumer advertising affect the stigma of mental illness?Community Mental Health Journal, 50(7), 792–799. https://doi.org/10.1007/s10597-014-9698-7
12.
EastR. (2003). The Effect of Advertising and Display: Assessing the Evidence. Kluwer.
13.
EatonM. L. (2004). Ethics and the business of bioscience. “Advertising Prescription Drugs Directly to Patients.”Stanford University Press.
14.
GoffmanE. (1963). Stigma: Notes on the Management of a Spoiled Identity. Prentice Hall.
15.
GreenbergG. (2010). Manufacturing Depression. Simon & Schuster.
HallS. (1975). Introduction. In SmithA. C. H.ImmiriziE.BlackwellT. (Eds.), Paper voices: The popular press and social change 1935–1965 (pp. 11–24). Chatto and Windus.
18.
HallS. (1980). Encoding/decoding. In HallS.HobsonD.LoweA.WillisP. (Eds.), Culture, media, language (pp. 128–138). Hutchinson.
HealyD. (2008). Mania: A short history of bipolar disorder. John Hopkins University Press.
22.
HoekJ. (2008). Ethical and practical implications of pharmaceutical direct-to-consumer advertising. International Journal of Nonprofit and Voluntary Sector Marketing, 13(February), 73–87. https://doi.org/10.1002/nvsm.319
23.
HoekJ.GendallP. (2002). To have or not to have? Ethics and regulation of direct to consumer advertising of prescription medicines. Journal of Marketing Communications, 8(2), 71–85. https://doi.org/10.1080/13527260210137181
24.
HorwitzA. V.WakefieldJ. C. (2007). The loss of sadness. Oxford University Press.
MartinE. (2007). Bipolar Expeditions: Mania and Depression in American Culture. Princeton University Press.
30.
MastinT.AndsagerJ. L.ChoiJ.LeeK. (2007). Health disparities and direct-to-consumer prescription drug advertising: A content analysis of targeted magazine genres, 1992–2002. Health Communication, 22(1), 49–58. https://doi.org/10.1080/10410230701310299
MoncrieffJ. (2014). The medicalisation of “ups and downs”: The marketing of the new bipolar disorder. Transcultural Psychiatry, 51(4), 581–598. https://doi.org/10.1177/1363461514530024
PreechavuthinantS.WillisW.CoustasseA. (2018). Trends and effects of pharmaceutical DTCA. International Journal of Pharmaceutical and Healthcare Marketing, 12(1), 61–70. https://doi.org/10.1108/IJPHM-04-2017-0019
37.
RosenthalM.DonohueJ. (2005). Direct-to-consumer advertising of prescription drugs: A policy dilemma. In SantoroM. A.GorrieT. M. (Eds.), Ethics and the pharmaceutical industry (pp. 169–183). Cambridge University Press.
38.
RossA. M.MorganA. J.JormA. F.ReavleyN. J. (2019). A systematic review of the impact of media reports of severe mental illness on stigma and discrimination, and interventions that aim to mitigate any adverse impact. Social Psychiatry and Psychiatric Epidemiology, 54(1), 11–31. https://doi.org/10.1007/s00127-018-1608-9
39.
ScheffT. J. (1974). The labelling theory of mental illness. American Sociological Review, 39(3), 444–452. https://doi.org/10.2307/2094349
40.
SharpeK. (2012). Coming of age on Zoloft. Harper Perennial.
41.
Skyquest (2022). Global bipolar disorder market size, share, growth analysis, by drug class (mood stabilizers, anticonvulsants), by type (bipolar I disorder, bipolar II disorder) - industry forecast 2022-2028. https://www.skyquestt.com/report/bipolar-disorder-market.
42.
SmardonR. (2007). 'I’d rather not take Prozac’: Stigma and commodification in antidepressant consumer narratives. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine, 12(1), 67–86. https://doi.org/10.1177/1363459307083698
43.
Stallybrass, P. & White, A. (1986). The politics and poetics of transgression. Methuen.
StepniskyJ. N. (2007). Narrative magic and the construction of selfhood in antidepressant advertising. Bulletin of Science, Technology & Society, 27(1), 24–36. https://doi.org/10.1177/0270467606295973
46.
Stout, P. A., Villegas, J., & Jennings, N. A. (2004). Images of mental illness in the media: Identifying gaps in the research. Schizophrenia Bulletin, 30(3), 543–561. https://doi.org/10.1093/oxfordjournals.schbul.a007099
47.
SullivanH. W.CampbellM. (2015). Do prescription drug ads tell consumers enough about benefits and side effects? Results from the health information national trends survey, fourth administration. Journal of Health Communication, 0730(February 2016), 1–6. https://doi.org/10.1080/10810730.2015.1018635
UssherJ. (2011). The madness of women: Myth and experience. Routledge.
50.
VentolaC. L. (2011). Direct-to-consumer pharmaceutical advertising therapeutic or toxic?P&T, 36(10), 669–684. PMID: 22346300.
51.
WalkerT. (2020). Ask Your Doctor About Chemical Imbalances: Mass-Communicating the Biomedical Model of Mental Illness Through the Selective Serotonin Reuptake Inhibitors, University of Colorado at Boulder.
52.
Wahl, O. F. (1995). Media madness: Public images of mental illness. Rutgers University Press.
53.
WalkerT. (2021). Resisting stigma and evaluating realism in a direct-to-consumer advertisement for psychiatric drugs. International Journal of Pharmaceutical and Healthcare Marketing, 15(4), 550–571. https://doi.org/10.1108/IJPHM-10-2019-0069
54.
WilkesM. S.BellR. A.KravitzR. L. (2000). Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs, 19(2), 110–128. https://doi.org/10.1377/hlthaff.19.2.110
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
